Meta AnalysisID 3092
香菇多糖静脉治疗肺癌的证据框架：一项聚类系统评价及Meta分析
CRD42022316824
The evidence framework of Lentinan intravenous therapy for lung cancer: whether Lentinan is effective and safe for patients with lung cancer? If the lentinan administration alone, are their effective? Is their clinical e
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3092
- Evidence Id
- 11650
- Core Evidence Id
- 11650
- Source Meta Analysis Id
- 3043
- Herb2 Meta Analysis Id
- HBMA003043
- Crd Id
- CRD42022316824
- Title
- The evidence framework of Lentinan intravenous therapy for lung cancer: a clustered systematic reviews and meta-analysis
- Review Question
- The evidence framework of Lentinan intravenous therapy for lung cancer: whether Lentinan is effective and safe for patients with lung cancer? If the lentinan administration alone, are their effective? Is their clinical effectiveness better than that of chemical agents and radiation therapy? How to combine lentinan with chemical drugs to achieve the desired effect and safety?
- Study Type Included
- We will include published and unpublished Chinese and English randomized controlled trials (RCTs) and cohort studies.
- Condition Being Studied
- Lung cancer is a highly malignant tumor that is easy to metastasize and relapse. It is also the main cause of cancer-related death. Tumor treatment, such as chemotherapy and radiotherapy, due to the lack of anti-tumor selective effect, not only inhibits tumor growth, but also has damage to normal cells and the body, affecting the therapeutic effect and increasing adverse reactions. The use of traditional Chinese medicine injection in the treatment of tumors is a popular tumor treatment method in bed in recent years. Lentinan (LTN) is a β-Glucan isolated and purified from the fruiting body of Lentinus edodes. It has strong antitumor activity. It is an anti-tumor adjuvant with immunomodulatory effect and a polysaccharide biological response regulator with improved immune function and multi-target anti-tumor effect. After years of clinical application and research, lentinan is helpful to the therapeutic effect of tumor and reduce adverse reactions. However, we did not systematically answer the effectiveness and safety of lentinan in the treatment of lung cancer alone and in combination, and the best treatment scheme.
- Participant
- All patients met the clinical diagnostic criteria of lung cancer, confirmed by imaging and pathological examination. There is no restriction on lung cancer classification and operation. Patients were older than 18 years of age and did not receive chemotherapy, radiotherapy, lentinan or similar bioreactors agents 1 month before treatment. Before medication, the functions of liver, kidney, heart and bone marrow were normal.
- Animal
- Human Disease Modelled
- Intervention
- The intervention measures are intravenous injection of lentinan, non-subcutaneous injection or thoracic perfusion. According to different medication schemes, it can be divided into medication alone and combined medication. The Medication alone Schemes of lentinan include: lentinan alone, lentinan vs placebo, lentinan vs chemotherapy, lentinan vs radiotherapy, lentinan vs chemoradiotherapy, lentinan vs other traditional Chinese medicine or biological reactants; The combined drug use of lentinan includes: lentinan plus chemotherapy vs chemotherapy, lentinan plus radiotherapy vs radiotherapy, lentinan plus chemoradiotherapy vs chemoradiotherapy.
- Comparator Control
- Non-lentinan treatment of lung cancer, lentinan treatment of non-lung cancer, non-intravenous treatment.
- Main Outcome
- The tumor response and quality of life (QOL) Measures of effect odds ratios (OR) or HR and their 95% confidence intervals (CI)
- Outcome Measure
- Additional Outcome
- Adverse events related to interventions Measures of effect odds ratios (OR) or HR and their 95% confidence intervals (CI)
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Humans; Lentinan; Lung Neoplasms
- Contact
- Xiaorong Huang [email protected]
- Organisational Affiliation
- GCP Center, Affiliated Hospital of Zunyi Medical University, Guizhou, China https://www.zmuhospital.com/
- Funding Source
- There is no.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-03-14
- Registration Date
- 2022-04-14
- Anticipated Start Date
- 2022-03-01
- Anticipated Completion Date
- 2022-09-01
- Title Cn
- 香菇多糖静脉治疗肺癌的证据框架：一项聚类系统评价及Meta分析
- Title En
- The evidence framework of Lentinan intravenous therapy for lung cancer: a clustered systematic reviews and meta-analysis
- Bilingual Status
- complete